Melinta_Therapeutics

Melinta Therapeutics

Melinta Therapeutics

American pharmaceutical company

Melinta Therapeutics, founded in 2000 as Rib-X Pharmaceuticals, is an American publicly traded biopharmaceutical firm that focuses on the design and development of novel broad-spectrum antibiotics for the treatment of antibiotic-resistant infections in hospital settings. The company is located in Parsippany, New Jersey.[1]

Quick Facts Industry, Founded ...

In mid-2011, Sanofi entered into a global research collaboration and licensing option with the company to develop and commercialize novel antibiotics.[2] It was renamed Melinta Therapeutics in 2013.[3]

One of its products, delafloxacin (Baxdela), a fluoroquinolone antibiotic acquired from Wakunaga Pharmaceutical in 2006,[2] was approved by the FDA in 2017.[4]

As of 2016, the company was also developing radezolid, a next-generation oxazolidinone for bacterial acne.[3]

Melinta shredded off its discovery research team in late 2018.[5] It also moved its headquarters from New Haven to Morristown, New Jersey in early 2019.

On December 27, 2019, Melinta Therapeutics filed for Chapter 11 bankruptcy protection.[6]

In April 2020, it was transferred to affiliates of its creditor Deerfield Management.[5]

References

  1. [1]
    Carroll, John (2011). "Rib-X Pharmaceuticals - 2011 Fierce 15". FierceBiotech.
  2. [2]
    Cartwright, Heather (12 July 2011). "Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi". PharmaDeals Review. No. 7. doi:10.3833/pdr.v2011i7.1494 (inactive 31 January 2024). Archived from the original on 25 April 2012.{{cite news}}: CS1 maint: DOI inactive as of January 2024 (link)
  3. [3]
    Stearns, John (August 1, 2016). "Melinta Therapeutics takes aim at deadly drug-resistant bacteria". Hartford Business Journal.
  4. [4]
    Osborne, Randy (20 June 2017). "Melinta's I.V., oral delafloxacin wins FDA nod in skin infections". BioWorld. Archived from the original on 3 August 2019. Retrieved 10 July 2017.
  5. [5]
    Missakian, Natalie (April 23, 2020). "Antibiotics maker Melinta emerges from bankruptcy under new ownership". Hartford Business. Retrieved 23 November 2022.
  6. [6]
    "Antibiotics maker Melinta files for Chapter 11 bankruptcy". Reuters. 2019-12-27. Retrieved 2019-12-29.

40.80164°N 74.45860°W / 40.80164; -74.45860
Share this article:

This article uses material from the Wikipedia article Melinta_Therapeutics, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.